Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.

Although the sublethal challenge dose-based infection model showed a clear trend toward effective protection due to the s.c. formulation compared with rNP alone, the protective efficacy against lethal infection remains elusive.

also in 12,136 other papers